Heart failure is characterised by contractile dysfunction caused by a decreased sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) activity. In September 18 Circulation, Federica del Monte and colleagues from Massachusetts General Hospital show that gene transfer of SERCA2a can improve survival and the energy potential in failing hearts.del Monte et al. tested the effects of adenoviral cardiac gene transfer of SERCA2a on survival, left ventricular (LV) volumes and metabolism in a rat model of heart fa
Heart failure is characterised by contractile dysfunction caused by a decreased sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) activity. In September 18
del Monte
"This study validates the feasibility of cardiac gene transfer in failing hearts as a therapeutic modality," said the authors.
In mammals, intracellular clocks begin to tick within days of fertilization.
View this Issue
Learn how mastering the ins and outs of PCR can accelerate workflows and improve data.
Polypharmacology allows scientists to explore novel therapeutic purposes for existing drugs and opens new doors to treat multifactorial diseases.
Molecular detection technologies help scientists rapidly and reliably find and address ever-evolving pathogens with optimal accuracy and sensitivity.
Discover the key features to consider when selecting a new refrigerator or freezer
On February 18, 2025, Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP).
Slow temperature recovery can threaten the integrity of your work. That’s Stirling Ultracold designed the VAULT100™ to operate at setpoints down to -100°C, so your samples may never be exposed to temperatures above -70°C during a typical door opening.
The next generation imager from the ChemiDoc Imaging System line. Effortlessly capture gel and western blot images from your benchtop without compromising on sensitivity and precision.
• Ongoing strategic partnership advances joint pipeline in neurodegeneration research
• Evotec receives a $20 million payment to further progress research
